ECM
EW icon

ExodusPoint Capital Management’s Edwards Lifesciences EW Stock Holding History

ExodusPoint Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,100
Closed -$168K – 2071
2020
Q3 		$168K Buy
+2,100
New +$164K ﹤0.01% 1521

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

ExodusPoint Capital Management's EW Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Edwards Lifesciences (EW) stake by 24% in Q1 2026, selling an estimated $5.7M and leaving 215,124 shares worth $17.2M. The position accounts for 0.14% of the portfolio, ranked #130.

ExodusPoint Capital Management first reported a position in EW in Q4 2018 and has held it in 18 quarters since. The position peaked at $24.2M in Q4 2025. 1,287 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • ExodusPoint Capital Management held 215,124 shares of Edwards Lifesciences worth $17.2M as of Q1 2026.
  • ExodusPoint Capital Management sold 69,168 Edwards Lifesciences shares in Q1 2026, an estimated $5.7M.
  • Edwards Lifesciences made up 0.14% of ExodusPoint Capital Management's portfolio in Q1 2026, its #130 holding.
  • ExodusPoint Capital Management first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 18 quarters since.
  • ExodusPoint Capital Management's Edwards Lifesciences position peaked at $24.2M in Q4 2025.
  • 1,287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.